Amgen Inc. AMGN
Amgen Inc. Stock Price Chart
Amgen Inc. Key Statistics
Fundamentals snapshot
Wall Street analyst ratings
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZL
This page tracks Amgen Inc.'s live share price, valuation multiples and the latest news. For how we source and present market data, see our methodology.
Latest Amgen Inc. news
We're expanding our Amgen Inc. coverage. In the meantime, browse the latest stock market news and live markets.
Other Healthcare stocks
Amgen Inc. (AMGN) FAQ
What is Amgen Inc. (AMGN)?
Amgen Inc. is a publicly traded company listed on NasdaqGS under the ticker AMGN. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZL
What is the AMGN stock price today?
Amgen Inc. (AMGN) is trading at $336.79, up 0.09% on the day. Prices on this page update through the trading session. This is not financial advice.
Is AMGN a buy?
Wall Street analysts currently rate AMGN a consensus "Buy", with an average 12-month price target of $352.23 (+4.59% vs the current price). Ratings are opinions, not guarantees — always do your own research.
When does Amgen Inc. report earnings?
The next Amgen Inc. earnings date is around Apr 30, 2026. Earnings dates can move — check the company's investor relations page to confirm.
Does AMGN pay a dividend?
Amgen Inc. pays a dividend with a current yield of about 2.99% ($10.08 per share annually).
Market data is provided for information only and may be delayed. Nothing on this page is investment advice or a recommendation to buy or sell AMGN. Markets are volatile and investing carries risk — always do your own research.